Biotech companies by P/B ratio
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Kodiak Sciences leads the 18 biotech companies ranked by P/B ratio, at 493, ahead of Scholar Rock Holding (34.3) and Adaptive Biotechnologies (26.1). Figures as of 18 Nov 2026, 19:33 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 18
- First
- Kodiak Sciences493
- Median
- 9.1
- Combined market value
- THB 28.38T
- Countries
- 5
- Not ranked
- 6no P/B ratio on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | P/B ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Kodiak SciencesKOD · Health Care | 493 | THB 214.7B | THB 3,283.08 | 0.13% down | 396% up | ||
| 2 | Scholar Rock HoldingSRRK · Health Care | 34.3 | THB 196.8B | THB 1,613.10 | 5.37% up | 14% up | ||
| 3 | Adaptive BiotechnologiesADPT · Health Care | 26.1 | THB 156.6B | THB 967.18 | 0.04% down | 88% up | ||
| 4 | AmgenAMGN · Health Care | 16.7 | THB 8.13T | THB 15,035.45 | 3.32% down | 34% up | ||
| 5 | Gilead SciencesGILD · Health Care | 16.0 | THB 7.09T | THB 5,716.49 | 1.13% down | 33% up | ||
| 6 | Revolution MedicinesRVMD · Health Care | 14.4 | THB 1.18T | THB 5,445.49 | 1.44% down | 131% up | ||
| 7 | ModernaMRNA · Health Care | 11.7 | THB 2.72T | THB 6,733.42 | 4.12% down | 755% up | ||
| 8 | ImmunovantIMVT · Health Care | 10.5 | THB 233.7B | THB 1,129.17 | 0.12% up | 43% up | ||
| 9 | ExelixisEXEL · Health Care | 9.1 | THB 567.8B | THB 2,327.11 | 0.04% up | 63% up | ||
| 10 | Twist BioscienceTWST · Health Care | 9.0 | THB 273.9B | THB 4,017.81 | 5.63% up | 340% up | ||
| 11 | CG OncologyCGON · Health Care | 7.1 | THB 240.6B | THB 2,693.37 | 0.47% up | 85% up | ||
| 12 | Krystal BiotechKRYS · Health Care | 6.5 | THB 315.1B | THB 10,633.73 | 4.88% up | 46% up | ||
| 13 | Kymera TherapeuticsKYMR · Health Care | 6.4 | THB 351.6B | THB 4,118.50 | 0.20% down | 87% up | ||
| 14 | Bio-TechneTECH · Health Care | 5.3 | THB 388.3B | THB 2,471.61 | 0.21% up | 26% up | ||
| 15 | RepligenRGEN · Health Care | 4.6 | THB 371.3B | THB 5,808.18 | 5.46% up | 5% up | ||
| 16 | Neurocrine BiosciencesNBIX · Health Care | 4.3 | THB 561.2B | THB 5,544.48 | 1.60% down | 20% up | ||
| 17 | VaxcytePCVX · Health Care | 3.5 | THB 313.4B | THB 1,979.87 | 1.85% down | 22% up | ||
| 18 | BiogenBIIB · Health Care | 2.0 | THB 1.26T | THB 8,492.38 | 0.29% down | 49% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 33.9600 THB). 6 companies have no P/B ratio on file and are not ranked here.
Questions and answers
Which biotech companies rank first by P/B ratio?
Kodiak Sciences (493), Scholar Rock Holding (34.3) and Adaptive Biotechnologies (26.1) are the top three of the 18 biotech companies ranked by P/B ratio as of 18 Nov 2026, 19:33 UTC.
How many biotech companies are in this ranking?
18 are ranked by P/B ratio. 6 more have no P/B ratio on file and are left out rather than ranked at zero.
What are these biotech companies worth together?
The 18 biotech companies ranked by P/B ratio have a combined market value of THB 28.38T as of 18 Nov 2026, 19:33 UTC.
What does ranking by P/B ratio measure?
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech companies by P/B ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=pb-ratio
Underlying data: Yahoo Finance; SEC EDGAR.